Modification of levodopa effect by systemic decarboxylase inhibition.
D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D004298:Dopamine / Q000097:blood; D004357:Drug Synergism; D004562:Electrocardiography; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008750:Methyldopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
D006834:Hydrazines; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D004298:Dopamine